Seeking Alpha·Jun 24, 2026
PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks TranscriptPAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript
PAVmed Inc.(PAVM)Earnings, Financials & Key Ratios
PAVM•NASDAQ
$5.25
Price updated Jul 7, 2026
AboutPAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Show more
- Revenue$71K-97.6%
- EBITDA-$22M+49.9%
- Net Income$401K-99.0%
- EPS (Diluted)-5.63-137.8%
- Gross Margin-354.93%-249.3%
- EBITDA Margin-30564.79%-2014.7%
- Operating Margin-30712.68%-1967.7%
- Net Margin564.79%-57.5%
- ROE5.25%
PAVM Price & Volume
PAVmed Inc. (PAVM) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten Corporate Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's precarious liquidity position
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Immediate insolvency and dilution
Key Thesis Takeaways
- PAVmed faces an existential crisis characterized by a near-total erosion of its commercial footprint and an unsustainable cost structure that consistently outpaces revenue generation.
- The company's reliance on non-operating accounting adjustments to mask core business failures, combined with a critical depletion of cash reserves, suggests a high probability of continued financial distress.
- Investors should remain cautious as the firm's inability to achieve positive free cash flow or maintain stable margins undermines the long-term viability of its medical device pipeline.
Verdict Logic
evidenced by a cash balance of only $1.5 million in 2025Q4, suggests an immediate risk of insolvency that outweighs any potential pipeline value.
PAVM Growth Metrics
PAVmed Inc. (PAVM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-42.68%
TTM1007.02%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-9572.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2086814.25%
Return on Capital
10 Years-864.15%
5 Years-319.07%
3 Years-419.99%
Last Year-227.28%
PAVM Recent Earnings
PAVmed Inc. (PAVM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (27%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$1.17-69.6%
$0.69
Rev
$22,000-70.3%
$74,000
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$1.05-50.0%
$0.70
Rev
—
$74,000
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$2.05+54.4%
$4.50
Rev
$52,000+108.0%
$25,000
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$8.41-39.9%
$6.01
Rev
$5,000-60.0%
$12,500
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $1.17vs $0.69-69.6% | $22,000vs $74,000-70.3% |
| Q2 2026 | Mar 30, 2026 | $1.05vs $0.70-50.0% | —vs $74,000 |
| Q2 2026 | Mar 26, 2026 | $2.05vs $4.50+54.4% | $52,000vs $25,000+108.0% |
| Q4 2025 | Nov 13, 2025 | $8.41vs $6.01-39.9% | $5,000vs $12,500-60.0% |
Based on last 12 quarters of dataView full earnings history →
Latest PAVM News
Recent stock market news and headlines for PAVmed Inc. (PAVM)
Peers Comparison
Key metrics vs top competitors for PAVmed Inc. (PAVM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.25 | $2.82M | -0.93 | -97.63% | 564.79% | 5.25% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $0.37 | $3.78M | -0.18 | -25.96% | -4632.94% | -120.72% | — | |
| $9.38 | $1.42B | -9.77 | 24.95% | -21.07% | -443.09% | — | |
| $150.65 | $8.82B | -45.93 | 32.33% | -34.34% | -26.46% | — |
Compare PAVM vs Peers
PAVmed Inc. (PAVM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PAVM SEC Filings & Documents
PAVmed Inc. (PAVM) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 27, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when PAVM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PAVM Frequently Asked Questions
PAVmed Inc. (PAVM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is PAVmed Inc.'s revenue?
PAVmed Inc. (PAVM) reported $22.1M in revenue for fiscal year 2025.
How fast is PAVmed Inc. growing?
PAVmed Inc. (PAVM) saw revenue decline by 97.6% over the past year.
Is PAVM profitable?
PAVmed Inc. (PAVM) reported a net loss of $7.01B for fiscal year 2025.
Dividend & Returns
What is PAVM's return on equity?
PAVmed Inc. (PAVM) has a return on equity (ROE) of 5.3%. This is below average, suggesting room for improvement.
What is PAVmed Inc.'s free cash flow?
PAVmed Inc. (PAVM) had negative free cash flow of $2.62B in fiscal year 2025, likely due to heavy capital investments.